All In Biotech

Drug Trial Radar · NCT06177912

A Clinical Study of the V116 Vaccine for Children and Teenagers (V116-013)

A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Children and Adolescents With Increased Risk of Pneumococcal Disease

Last checked: Nov 19, 2026Latest source record: Mar 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 882 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

882

Actual

Start

Jan 18, 2024

Primary completion

Feb 26, 2025

Study completion Feb 26, 2025

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Dec 20, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of V116 compared to PPSV23 in children and teenagers 2 through 17 years of age, who had completed routine pneumococcal vaccine as infants/toddlers. Researchers want to learn if V116 is as good as, or is better than the PPSV23 vaccine in terms of the antibody immune response. V116 and PPSV23 will be studied in children and teenagers who have a higher risk of getting pneumococcal disease (PD).

Conditions

  • Pneumococcal Infection

Interventions

  • V116Biological

    Pneumococcal 21-valent conjugate vaccine with 4 μg of each of the following pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution

  • PPSV23Biological

    Pneumococcal 23-valent conjugate vaccine with 25 μg of each of the following PnPs antigen: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in each 0.5 mL sterile solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Solicited Injection-site Adverse Events (AEs)Time frame: Up to 5 days postvaccination
  2. Percentage of Participants With Solicited Systemic AEsTime frame: Up to 5 days post vaccination
  3. Percentage of Participants With Vaccine-related Serious Adverse Events (SAEs)Time frame: Up to approximately 6 months
  4. Geometric Mean Titer of Serotype-specific Opsonophagocytic Activity (OPA) ResponsesTime frame: 30 days postvaccination

Locations

92 sites in 13 countries. Site status is shown where the registry gives one.

  • Central Research Associates ( Site 0145)

    Birmingham, Alabama

  • Velocity Clinical Research, Phoenix ( Site 0122)

    Phoenix, Arizona

  • Madera Family Medical Group ( Site 0120)

    Madera, California

  • Optumcare Colorado Springs, LLC ( Site 0113)

    Colorado Springs, Colorado

  • Accel Research Sites Network- Nona Pediatric Center ( Site 0109)

    Orlando, Florida

  • University of South Florida-Department of Pediatrics ( Site 0110)

    Tampa, Florida

  • Velocity Clinical Research at Primary Pediatrics, Macon ( Site 0128)

    Macon, Georgia

  • Bingham Memorial Hospital ( Site 0149)

    Blackfoot, Idaho

  • Clinical Research Prime ( Site 0105)

    Idaho Falls, Idaho

  • Clinical Research Prime Rexburg ( Site 0104)

    Rexburg, Idaho

  • University of Louisville, Norton Children's Research Institute ( Site 0148)

    Louisville, Kentucky

  • Velocity Clinical Research, Lafayette ( Site 0103)

    Lafayette, Louisiana

  • Velocity Clinical Research, Gulfport ( Site 0115)

    Gulfport, Mississippi

  • Velocity Clinical Research, Hastings ( Site 0114)

    Hastings, Nebraska

  • Midwest Children's Health Research Institute ( Site 0117)

    Lincoln, Nebraska

  • Midwest Children's Health Research Institute ( Site 0106)

    Lincoln, Nebraska

  • Midwest Children's Health Research Institute-Research ( Site 0119)

    Lincoln, Nebraska

  • Midwest Children's Health Research Institute-Research ( Site 0102)

    Lincoln, Nebraska

  • Velocity Clinical Research, Albuquerque ( Site 0112)

    Albuquerque, New Mexico

  • Velocity Clinical Research, Vestal ( Site 0121)

    Vestal, New York

  • Epic Medical Research - Oklahoma ( Site 0134)

    Chickasha, Oklahoma

  • Tribe Clinical Research, LLC-Pediatrics ( Site 0118)

    Greenville, South Carolina

  • Tribe Clinical Research - Spartanburg ( Site 0108)

    Spartanburg, South Carolina

  • Velocity Clinical Research, Austin ( Site 0129)

    Austin, Texas

  • PanAmerican Clinical Research ( Site 0132)

    Brownsville, Texas

  • Epic Medical Research ( Site 0133)

    DeSoto, Texas

  • Epic Medical Research - Mesquite ( Site 0144)

    Mesquite, Texas

  • Alliance for Multispecialty Research, LLC ( Site 0140)

    Layton, Utah

  • Velocity Clinical Research, Salt Lake City ( Site 0124)

    West Jordan, Utah

  • Canadian Center for Vaccinology ( Site 0004)

    Halifax, Nova Scotia, Canada

  • Premier Clinical Trial Network ( Site 0008)

    Hamilton, Ontario, Canada

  • Children's Hospital of Eastern Ontario ( Site 0001)

    Ottawa, Ontario, Canada

  • CHU Sainte-Justine ( Site 0007)

    Montreal, Quebec, Canada

  • McGill University Health Centre - Vaccine Study Centre ( Site 0005)

    Pierrefonds, Quebec, Canada

  • CHU de Québec-Université Laval ( Site 0006)

    Québec, Quebec, Canada

  • Hospital Dr. Hernán Henríquez Aravena ( Site 0208)

    Temuco, Araucania, Chile

  • Centro de Estudios Clínicos (ICIM, Facultad de Medicina Clínica Alemana Universidad del Desarrollo)

    Santiago, Region M. de Santiago, Chile

  • Pontificia Universidad Catolica de Chile-Pediatric Infectious Diseases and Immunology ( Site 0209)

    Santiago, Region M. de Santiago, Chile

  • Hospital Roberto del Río-Infectología Pediátrica ( Site 0200)

    Santiago, Region M. de Santiago, Chile

  • Hospital Padre Hurtado-NEONATOLOGY/PEDIATRICS ( Site 0204)

    Santiago, Region M. de Santiago, Chile

Showing 40 of 92 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.